Evaluation of mitogillin (NSC-69529) in the treatment of naturally occurring canine neoplasms.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D004283:Dog Diseases; D004285:Dogs; D004304:Dosage Forms; D000882:Haplorhini; D007275:Injections, Intravenous; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008321:Mammary Glands, Animal; D012515:Mast-Cell Sarcoma / Q000188:drug therapy*; D051379:Mice; D010455:Peptides / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D004304:Dosage Forms; D010455:Peptides